Hisun Pharma to Supply Celsion’s Proprietary Cancer Drug

Did you know?

ChinaBio^® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…

More white papers:

>>China Partnering 2012: Driving Future Innovation

>>China Life Science 2012: From Local to Global

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Subscriber Content

Hisun Pharma to Supply Celsion’s Proprietary Cancer Drug

publication date: May 15, 2012

Zhejiang Hisun Pharma was chosen to be the commercial supplier of ThermoDox®, a clinical-stage liver cancer drug developed by Celsion of the US. ThermoDox® is Celsion's proprietary liposomal encapsulation of doxorubicin. Hisun positioned the agreement as a step toward developing a portfolio of branded generics products. In February of this year, Hisun announced a $245 million JV with Pfizer, a project also devoted to branded generics. More details.....

Stock Symbols: (SHA: 600267) (NSDQ: CLSN) (NYSE: PFE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Click here to join.